Novartis erzielt im zweiten Quartal weiterhin kräftige Umsatzsteigerungen und erhöht die Kerngewinnmarge; Gewinnprognose für das Geschäftsjahr 2024 angehoben
arcticnovartis
Thu, 07/18/2024 – 07:03
Read more about Novartis erzielt im zweiten Quarta…
Novartis a poursuivi au T2 la forte croissance de son chiffre d’affaires et l’expansion de sa marge core; hausse des prévisions de son résultat opérationnel core pour 2024
arcticnovartis
Thu, 07/18/2024 – 07:03
Read more about Novartis a poursuivi…
Novartis a poursuivi au T2 la forte croissance de son chiffre d’affaires et l’expansion de sa marge core; hausse des prévisions de son résultat opérationnel core pour 2024
arcticnovartis
Thu, 07/18/2024 – 07:03
Read more about Novartis a poursuivi…
Novartis continues to deliver strong sales growth and core margin expansion in Q2; raises FY 2024 bottom-line guidance
arcticnovartis
Thu, 07/18/2024 – 07:03
Read more about Novartis continues to deliver strong sales growth and core margin expansi…
Latest analysis of Novartis NATALEE study shows Kisqali® reduces risk of cancer recurrence for early breast cancer patients with high-risk node-negative disease
arcticnovartis
Fri, 05/31/2024 – 14:19
Read more about Latest analysis of No…
Latest analysis of Novartis NATALEE study shows Kisqali® reduces risk of cancer recurrence for early breast cancer patients with high-risk node-negative disease
arcticnovartis
Fri, 05/31/2024 – 14:19
Read more about Latest analysis of No…
Novartis Scemblix® Phase III data first to show superior efficacy with a favorable safety and tolerability profile vs. standard-of-care TKIs in adults with newly diagnosed CML
arcticnovartis
Fri, 05/31/2024 – 14:04
Read more about Novartis Scembl…
Novartis Scemblix® Phase III data first to show superior efficacy with a favorable safety and tolerability profile vs. standard-of-care TKIs in adults with newly diagnosed CML
arcticnovartis
Fri, 05/31/2024 – 14:04
Read more about Novartis Scembl…
Novartis Phase III data confirm sustained efficacy and long-term safety of oral remibrutinib in chronic spontaneous urticaria
arcticnovartis
Fri, 05/31/2024 – 00:04
Read more about Novartis Phase III data confirm sustained efficacy and long-term s…
Novartis atrasentan Phase III data show clinically meaningful proteinuria reduction further advancing company’s IgA nephropathy (IgAN) portfolio
arcticnovartis
Sat, 05/25/2024 – 12:19
Read more about Novartis atrasentan Phase III data show clinica…
